STAAR Surgical Company (STAA) Fair Value & Analysis

Healthcare · US · Market cap $1.4B · ISIN US8523123052

What is STAAR Surgical Company really worth?

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case ($4.87). The favourable scenario is already priced in.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range ($2.57 to $4.87) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.

How to read this chart

60‑month range $15.09 – $162.68 · fair‑value band $2.57 – $4.87 · the $23.47 price screens above the $3.90 fair value. Dashed = 300-day average. As of Aug 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

STAAR Surgical Company (STAA) currently trades at $23.47, while our model-based Fair Value estimate is $3.90, implying the stock looks roughly 501.7% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.

Over the trailing twelve months, STAAR Surgical Company generated revenue of $290M at a net margin of −7.2%. Revenue grew 119.6% year over year. It earns a return on equity of −6.0%. The balance sheet holds a net cash position of $115M. Fundamentals as of Aug 22, 2026

Our scenario range runs from $2.57 (bear case) to $4.87 (bull case); at $23.47, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 51% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −46% fair-value upside, at −83%, STAA screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Key figures & financial health

Quality Score breakdown

About the company

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.

Full company description

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

STAAR Surgical Company reported revenue of $239M in FY2025 versus $230M in FY2021, a compound +1.0%/yr. Reported net income was −$80.4M in FY2025.

STAA screens 502% overvalued. Compare with Intuitive Surgical, Inc →

Peer Group

Medical Instruments & Supplies · 194 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Insider activity: 66/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions